{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:19:19Z","timestamp":1791537559510,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272623"],"award-info":[{"award-number":["82272623"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073410"],"award-info":[{"award-number":["82073410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR\u2009+\u2009\/HER2\u2009\u2212\u2009) breast cancer, the most common subtype, shows a low pathological complete response (pCR) rate and limited benefit from immunotherapy, highlighting the need for more effective strategies. Although immunotherapy has become increasingly important in cancer treatment, its efficacy in this subtype remains modest. CDK4\/6 inhibitors, first-line treatments for advanced HR\u2009+\u2009\/HER2\u2212 breast cancer, not only suppress tumor proliferation but may also reshape the immune microenvironment, offering new opportunities for immunotherapy. In this study, multiplex immunohistochemistry, drug testing of HR\u2009+\u2009\/HER2\u2212 breast cancer organoids, single-cell sequencing, and primary cell coculture showed that the CDK4\/6 inhibitor palbociclib promotes fibroblast senescence, thereby increasing IGF1 and FGF7 levels. These factors drive macrophage polarization toward an M2-like phenotype through STAT3 Tyr705 phosphorylation and ARG1 upregulation, resulting in arginine depletion and reduced lymphocyte viability. To counteract this immunosuppressive microenvironment, we selected the CSF1R inhibitor pexidartinib. Pexidartinib inhibited macrophage activity, suppressed STAT3 phosphorylation, reduced ARG1 expression, and increased lymphocyte viability, thereby enhancing the antitumor efficacy of palbociclib in HR\u2009+\u2009\/HER2\u2212 breast cancer. These findings reveal a previously unrecognized immunosuppressive mechanism induced by CDK4\/6 inhibition and support CSF1R blockade as a promising combination strategy.<\/jats:p>","DOI":"10.1038\/s41388-026-03786-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:57:27Z","timestamp":1776250647000},"page":"1970-1987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CSF1R inhibitors mitigate CDK4\/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+\/HER2\u2212 breast cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6642-9859","authenticated-orcid":false,"given":"Siwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiyasi","family":"Nanding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-2361","authenticated-orcid":false,"given":"Xianyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-4170","authenticated-orcid":false,"given":"Da","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"3786_CR1","doi-asserted-by":"publisher","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","volume":"160","author":"R Torrisi","year":"2021","unstructured":"Torrisi R, Marrazzo E, Agostinetto E, De Sanctis R, Losurdo A, Masci G, et al. Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what? Crit Rev Oncol\/Hematol. 2021;160:103280.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"3786_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00432-022-03938-x","volume":"149","author":"O Ortmann","year":"2023","unstructured":"Ortmann O, Blohmer J-U, Sibert NT, Brucker S, Janni W, W\u00f6ckel A, et al. Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers. J Cancer Res Clin Oncol. 2023;149:1195\u2013209.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3786_CR3","doi-asserted-by":"crossref","unstructured":"Cottu P, D\u2019Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel P-E et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29:2334\u201340.","DOI":"10.1093\/annonc\/mdy448"},{"key":"3786_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/cco-20-123","volume":"9","author":"M Takada","year":"2020","unstructured":"Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9:32\u201332.","journal-title":"Chin Clin Oncol"},{"key":"3786_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.13176","volume":"314","author":"BB Antuamwine","year":"2023","unstructured":"Antuamwine BB, Bosnjakovic R, Hofmann-Vega F, Wang X, Theodosiou T, Iliopoulos I, et al. N1 versus N2 and PMN-MDSC: a critical appraisal of current concepts on tumor-associated neutrophils and new directions for human oncology. Immunol Rev. 2023;314:250\u201379.","journal-title":"Immunol Rev"},{"key":"3786_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3390\/cancers14020307","volume":"14","author":"M N\u00fa\u00f1ez Abad","year":"2022","unstructured":"N\u00fa\u00f1ez Abad M, Calabuig-Fari\u00f1as S, Lobo De Mena M, Torres-Mart\u00ednez S, Garc\u00eda Gonz\u00e1lez C, Garc\u00eda Garc\u00eda J\u00c1, et al. Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer. Cancers. 2022;14:307.","journal-title":"Cancers"},{"key":"3786_CR7","doi-asserted-by":"publisher","unstructured":"Onkar S, Cui J, Zou J, Cardello C, Cillo AR, Uddin MR et al. Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment. Nat Cancer 2023. https:\/\/doi.org\/10.1038\/s43018-023-00527-w.","DOI":"10.1038\/s43018-023-00527-w"},{"key":"3786_CR8","doi-asserted-by":"publisher","first-page":"106517","DOI":"10.1016\/j.jsbmb.2024.106517","volume":"240","author":"C McGuinness","year":"2024","unstructured":"McGuinness C, Britt KL. Estrogen receptor regulation of the immune microenvironment in breast cancer. J Steroid Biochem Mol Biol. 2024;240:106517.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3786_CR9","doi-asserted-by":"publisher","first-page":"113059","DOI":"10.1016\/j.intimp.2024.113059","volume":"142","author":"S Li","year":"2024","unstructured":"Li S, Zhang X, Pang D. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+\/HER2\u2212 breast cancer. Int Immunopharmacol. 2024;142:113059.","journal-title":"Int Immunopharmacol"},{"key":"3786_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022;22:356\u201372.","journal-title":"Nat Rev Cancer"},{"key":"3786_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","volume":"20","author":"G Petroni","year":"2020","unstructured":"Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20:669\u201379.","journal-title":"Nat Rev Immunol"},{"key":"3786_CR12","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, et al. Inhibition of CDK4\/6 promotes CD8 T-cell memory formation. Cancer Discov. 2021;11:2564\u201381.","journal-title":"Cancer Discov"},{"key":"3786_CR13","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","volume":"11","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, Kong IY, Zethoven M, Ramsbottom KM, Martelotto LG, Meyran D, et al. CDK4\/6 inhibition promotes antitumor immunity through the Induction of T-cell memory. Cancer Discov. 2021;11:2582\u2013601.","journal-title":"Cancer Discov"},{"key":"3786_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216\u201333.","journal-title":"Cancer Discov"},{"key":"3786_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2021.11.025","volume":"162","author":"CA Peuker","year":"2022","unstructured":"Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Gjerga E, Hennig S, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer\u2014findings from the RIBECCA trial. Eur J Cancer. 2022;162:45\u201355.","journal-title":"Eur J Cancer"},{"key":"3786_CR16","doi-asserted-by":"publisher","first-page":"104010","DOI":"10.1016\/j.ebiom.2022.104010","volume":"79","author":"F Scirocchi","year":"2022","unstructured":"Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, et al. Immune effects of CDK4\/6 inhibitors in patients with HR\u2009+\u2009\/HER2\u2212 metastatic breast cancer: Relief from immunosuppression is associated with clinical response. Ebiomedicine. 2022;79:104010.","journal-title":"Ebiomedicine"},{"key":"3786_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance. Nature. 2018;553:91\u20135.","journal-title":"Nature"},{"key":"3786_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","volume":"22","author":"R Di Micco","year":"2021","unstructured":"Di Micco R, Krizhanovsky V, Baker D, d\u2019Adda, di Fagagna F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Bio. 2021;22:75\u201395.","journal-title":"Nat Rev Mol Cell Bio"},{"key":"3786_CR19","unstructured":"NCCN Guidelines Breast Cancer, NCCN clinical practice guidelines in oncology \u2013 Breast Cancer(2023 Version IV)[DB\/OL]. http:\/\/www.nccn.org."},{"key":"3786_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.36401\/JIPO-20-32","volume":"4","author":"C-C Lin","year":"2021","unstructured":"Lin C-C. Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors. J Immunother Precis Oncol. 2021;4:105\u201314.","journal-title":"J Immunother Precis Oncol"},{"key":"3786_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2020","unstructured":"Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2020;2:66\u201382.","journal-title":"Nat Cancer"},{"key":"3786_CR22","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.21873\/anticanres.13565","volume":"39","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, et al. Sorafenib and palbociclib combination regresses a cisplatinum-resistant osteosarcoma in a PDOX mouse model. Anticancer Res. 2019;39:4079\u201384.","journal-title":"Anticancer Res"},{"key":"3786_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1158\/2159-8290.CD-17-0535","volume":"8","author":"KJ Matissek","year":"2018","unstructured":"Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, et al. Expressed gene fusions as frequent drivers of poor outcomes in hormone receptor\u2013positive. Breast Cancer Cancer Discov. 2018;8:336\u201353.","journal-title":"Breast Cancer Cancer Discov"},{"key":"3786_CR24","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-19-2706","volume":"26","author":"JL Kohlmeyer","year":"2020","unstructured":"Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Samayoa AM, Major HJ, et al. RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4\/6 inhibitors. Clin Cancer Res. 2020;26:2997\u20133011.","journal-title":"Clin Cancer Res"},{"key":"3786_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08380-1","volume":"10","author":"Y Xue","year":"2019","unstructured":"Xue Y, Meehan B, Fu Z, Wang XQD, Fiset PO, Rieker R, et al. SMARCA4 loss is synthetic lethal with CDK4\/6 inhibition in non-small cell lung cancer. Nat Commun. 2019;10:557.","journal-title":"Nat Commun"},{"key":"3786_CR26","doi-asserted-by":"publisher","first-page":"e104230","DOI":"10.1371\/journal.pone.0104230","volume":"9","author":"M Sluijter","year":"2014","unstructured":"Sluijter M, van der Sluis TC, van der Velden PA, Versluis M, West BL, van der Burg SH, et al. Inhibition of CSF-1R Supports T-cell mediated melanoma therapy. PLoS ONE. 2014;9:e104230.","journal-title":"PLoS ONE"},{"key":"3786_CR27","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","volume":"35","author":"JG Valero","year":"2021","unstructured":"Valero JG, Matas-C\u00e9spedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;35:2635\u201349.","journal-title":"Leukemia"},{"key":"3786_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02118-x","volume":"18","author":"MM Boyd","year":"2021","unstructured":"Boyd MM, Litscher SJ, Seitz LL, Messing A, Hagemann TL, Collier LS. Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes. J Neuroinflammation. 2021;18:67.","journal-title":"J Neuroinflammation"},{"key":"3786_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","volume":"74","author":"S Mok","year":"2014","unstructured":"Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74:153\u201361.","journal-title":"Cancer Res"},{"key":"3786_CR30","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1161\/STROKEAHA.115.009426","volume":"46","author":"HX Chu","year":"2015","unstructured":"Chu HX, Broughton BRS, Ah Kim H, Lee S, Drummond GR, Sobey CG. Evidence that Ly6Chi monocytes are protective in acute ischemic stroke by promoting M2 macrophage polarization. Stroke. 2015;46:1929\u201337.","journal-title":"Stroke"},{"key":"3786_CR31","doi-asserted-by":"publisher","first-page":"H906","DOI":"10.1152\/ajpheart.00821.2014","volume":"309","author":"JP Moore","year":"2015","unstructured":"Moore JP, Vinh A, Tuck KL, Sakkal S, Krishnan SM, Chan CT, et al. M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure. Am J Physiol-Heart Circul Physiol. 2015;309:H906\u201317.","journal-title":"Am J Physiol-Heart Circul Physiol"},{"key":"3786_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01472-1","volume":"23","author":"J Hazlett","year":"2021","unstructured":"Hazlett J, Niemi V, Aiderus A, Powell K, Wise L, Kemp R, et al. Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. Breast Cancer Res. 2021;23:95.","journal-title":"Breast Cancer Res"},{"key":"3786_CR33","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.7150\/thno.49421","volume":"11","author":"Q Cao","year":"2021","unstructured":"Cao Q, Huang Q, Wang YA, Li C. Abraxane-induced bone marrow CD11b + myeloid cell depletion in tumor-bearing mice is visualized by \u03bcPET-CT with 64 Cu-labeled anti-CD11b and prevented by anti-CSF-1. Theranostics. 2021;11:3527\u201339.","journal-title":"Theranostics"},{"key":"3786_CR34","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1002\/imt2.217","volume":"3","author":"C Han","year":"2024","unstructured":"Han C, Shi C, Liu L, Han J, Yang Q, Wang Y, et al. Majorbio cloud 2024: update single-cell and multiomics workflows. iMeta. 2024;3:e217.","journal-title":"iMeta"},{"key":"3786_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cancers12010223","volume":"12","author":"B Alday-Parejo","year":"2020","unstructured":"Alday-Parejo B, Richard F, W\u00f6rthm\u00fcller J, Rau T, Galv\u00e1n JA, Desmedt C, et al. MAGI1, a new potential tumor suppressor gene in estrogen receptor positive breast cancer. Cancers. 2020;12:223.","journal-title":"Cancers"},{"key":"3786_CR36","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.3390\/ijms24065666","volume":"24","author":"M Lambouras","year":"2023","unstructured":"Lambouras M, Roelofs C, Pereira M, Gruber E, Vieusseux JL, Lanteri P, et al. Functional and phenotypic characterisations of common syngeneic tumour cell lines as estrogen receptor-positive breast cancer models. IJMS. 2023;24:5666.","journal-title":"IJMS"},{"key":"3786_CR37","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","volume":"36","author":"A Zlotnik","year":"2012","unstructured":"Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36:705\u201316.","journal-title":"Immunity"},{"key":"3786_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41420-022-01200-4","volume":"8","author":"Z Li","year":"2022","unstructured":"Li Z, Wang L, Ren Y, Huang Y, Liu W, Lv Z, et al. Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell Death Discov. 2022;8:413.","journal-title":"Cell Death Discov"},{"key":"3786_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cas.12932","volume":"107","author":"K Tamura","year":"2016","unstructured":"Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, et al. Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients. Cancer Sci. 2016;107:755\u201363.","journal-title":"Cancer Sci"},{"key":"3786_CR40","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1172\/JCI60083","volume":"123","author":"D Vasquez-Dunddel","year":"2013","unstructured":"Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest. 2013;123:1580\u20139.","journal-title":"J Clin Invest"},{"key":"3786_CR41","doi-asserted-by":"publisher","first-page":"e145296","DOI":"10.1172\/JCI145296","volume":"131","author":"X Su","year":"2021","unstructured":"Su X, Xu Y, Fox GC, Xiang J, Kwakwa KA, Davis JL, et al. Breast cancer\u2013derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment. J Clin Investig. 2021;131:e145296.","journal-title":"J Clin Investig"},{"key":"3786_CR42","doi-asserted-by":"publisher","first-page":"e74690","DOI":"10.7554\/eLife.74690","volume":"11","author":"ML Lundahl","year":"2022","unstructured":"Lundahl ML, Mitermite M, Ryan DG, Case S, Williams NC, Yang M, et al. Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses. eLife. 2022;11:e74690.","journal-title":"eLife"},{"key":"3786_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.","journal-title":"BMC Cancer"},{"key":"3786_CR44","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2184.2006.00410.x","volume":"39","author":"M Inchovska","year":"2006","unstructured":"Inchovska M, Ogneva V, Martinova Y. Role of FGF1, FGF2 and FGF7 in the development of the pancreas from control and streptozotocin-treated hamsters. Cell Prolif. 2006;39:537\u201350.","journal-title":"Cell Prolif"},{"key":"3786_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52741-1","volume":"9","author":"K Lin","year":"2019","unstructured":"Lin K, Ma J, Peng Y, Sun M, Xu K, Wu R, et al. Autocrine Production of Interleukin-34 Promotes the Development of Endometriosis through CSF1R\/JAK3\/STAT6 signaling. Sci Rep. 2019;9:16781.","journal-title":"Sci Rep"},{"key":"3786_CR46","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3899\/jrheum.151253","volume":"43","author":"S Yang","year":"2016","unstructured":"Yang S, Jiang S, Wang Y, Tu S, Wang Z, Chen Z. Interleukin 34 upregulation contributes to the increment of MicroRNA 21 expression through STAT3 activation associated with disease activity in rheumatoid arthritis. J Rheumatol. 2016;43:1312\u20139.","journal-title":"J Rheumatol"},{"key":"3786_CR47","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara T, Yakoub MA, Chandler A, Christ AB, Yang G, Ouerfelli O, et al. CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Therapeutics. 2021;20:1388\u201399.","journal-title":"Mol Cancer Therapeutics"},{"key":"3786_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/nri1668","volume":"5","author":"V Bronte","year":"2005","unstructured":"Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641\u201354.","journal-title":"Nat Rev Immunol"},{"key":"3786_CR49","doi-asserted-by":"publisher","unstructured":"Creason AL, Egger J, Watson C, Sivagnanam S, Chin K, MacPherson K et al. \u201cLongitudinal and multimodal auditing of tumor adaptation to CDK4\/6 inhibitors in HR+ metastatic breast cancers\u201d. Cancer Biology, 2023 https:\/\/doi.org\/10.1101\/2023.09.27.557464.","DOI":"10.1101\/2023.09.27.557464"},{"key":"3786_CR50","doi-asserted-by":"publisher","first-page":"108944","DOI":"10.1016\/j.celrep.2021.108944","volume":"35","author":"RV Uzhachenko","year":"2021","unstructured":"Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, et al. Metabolic modulation by CDK4\/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep. 2021;35:108944.","journal-title":"Cell Rep"},{"key":"3786_CR51","first-page":"A763","volume":"9","author":"G Petroni","year":"2021","unstructured":"Petroni G, Gouin K, Martinez AB, Knott S, Formenti S, Galluzzi L. 733 Immunological mechanisms of resistance to CDK4\/CDK6 inhibitors in breast cancer. J Immunother Cancer. 2021;9:A763\u2013A763.","journal-title":"J Immunother Cancer"},{"key":"3786_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135.","journal-title":"Nature"},{"key":"3786_CR53","doi-asserted-by":"crossref","unstructured":"Lelliott EJ, Mangiola S, Ramsbottom KM, Zethoven M, Lim L, Lau PKH et al. Combined BRAF, MEK, and CDK4\/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma. Cancer Immunol Res. 2021;9:136\u2013146.","DOI":"10.1158\/2326-6066.CIR-20-0401"},{"key":"3786_CR54","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.celrep.2018.02.053","volume":"22","author":"DA Schaer","year":"2018","unstructured":"Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4\/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22:2978\u201394.","journal-title":"Cell Rep"},{"key":"3786_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02226-9","volume":"24","author":"L Luo","year":"2025","unstructured":"Luo L, Yang P, Mastoraki S, Rao X, Wang Y, Kettner NM, et al. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4\/6 inhibition in patients with HR+\/HER2- metastatic breast cancer. Mol Cancer. 2025;24:48.","journal-title":"Mol Cancer"},{"key":"3786_CR56","doi-asserted-by":"crossref","unstructured":"Lim C. High-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple negative breast cancer. Nano Today 2023;51:101884.","DOI":"10.1016\/j.nantod.2023.101884"},{"key":"3786_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc3078","volume":"11","author":"ET Roussos","year":"2011","unstructured":"Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573\u201387.","journal-title":"Nat Rev Cancer"},{"key":"3786_CR58","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2017.35.15_suppl.1097","volume":"35","author":"JM Patel","year":"2017","unstructured":"Patel JM, Torous V, Hacker MR, Nalven T, Garber JE, Alexander BM, et al. Retinoblastoma (Rb) protein expression in triple-negative breast cancer. JCO. 2017;35:1097.","journal-title":"JCO"},{"key":"3786_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/jco.2015.33.28_suppl.126","volume":"33","author":"GD Basu","year":"2015","unstructured":"Basu GD, White T, LoBello JR, Kurdoglu A, Krishnan S, Gonzalez L, et al. Alterations in the cell cycle checkpoint pathway in breast cancer. JCO. 2015;33:126.","journal-title":"JCO"},{"key":"3786_CR60","doi-asserted-by":"publisher","first-page":"1019313","DOI":"10.3389\/fimmu.2022.1019313","volume":"13","author":"Z Yue","year":"2022","unstructured":"Yue Z, Nie L, Zhao P, Ji N, Liao G, Wang Q. Senescence-associated secretory phenotype and its impact on oral immune homeostasis. Front Immunol. 2022;13:1019313.","journal-title":"Front Immunol"},{"key":"3786_CR61","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","volume":"79","author":"PJ Murray","year":"2017","unstructured":"Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541\u201366.","journal-title":"Annu Rev Physiol"},{"key":"3786_CR62","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Sig Transduct Target Ther. 2021;6:127.","journal-title":"Sig Transduct Target Ther"},{"key":"3786_CR63","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/ijms18071545","volume":"18","author":"M Hesketh","year":"2017","unstructured":"Hesketh M, Sahin KB, West ZE, Murray RZ. Macrophage phenotypes regulate scar formation and chronic wound healing. IJMS. 2017;18:1545.","journal-title":"IJMS"},{"key":"3786_CR64","doi-asserted-by":"publisher","first-page":"5243","DOI":"10.1158\/1078-0432.CCR-07-0182","volume":"13","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13:5243\u20138.","journal-title":"Clin Cancer Res"},{"key":"3786_CR65","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.1158\/1538-7445.AM2023-5693","volume":"83","author":"JI Griffiths","year":"2023","unstructured":"Griffiths JI, Cosgrove PA, Castaneda EM, Nath A, Chen J, Adler FR, et al. Abstract 5693: Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER+ breast cancer. Cancer Res. 2023;83:5693.","journal-title":"Cancer Res"},{"key":"3786_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2671-1","volume":"11","author":"J-B Ma","year":"2020","unstructured":"Ma J-B, Bai J-Y, Zhang H-B, Jia J, Shi Q, Yang C, et al. KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1. Cell Death Dis. 2020;11:466.","journal-title":"Cell Death Dis"},{"key":"3786_CR67","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10637-021-01061-1","volume":"39","author":"X Song","year":"2021","unstructured":"Song X, Tang W, Peng H, Qi X, Li J. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Invest N Drugs. 2021;39:1201\u201312.","journal-title":"Invest N Drugs"},{"key":"3786_CR68","doi-asserted-by":"publisher","first-page":"e13022","DOI":"10.1111\/cpr.13022","volume":"54","author":"X Xu","year":"2021","unstructured":"Xu X, Feng Z, Cao D, Wu H, Wang M, Li J, et al. SCARF1 promotes M2 polarization of Kupffer cells via calcium-dependent PI3K-AKT-STAT3 signalling to improve liver transplantation. Cell Prolif. 2021;54:e13022.","journal-title":"Cell Prolif"},{"key":"3786_CR69","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13574","volume":"168","author":"Y Gou","year":"2023","unstructured":"Gou Y, Wang H, Wang T, Wang H, Wang B, Jiao N, et al. Ectopic endometriotic stromal cells-derived lactate induces M2 macrophage polarization via Mettl3\/Trib1\/ ERK \/ STAT3\/ signalling pathway in endometriosis. Immunology. 2023;168:389\u2013402.","journal-title":"Immunology"},{"key":"3786_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-60819-8","volume":"14","author":"MDM Noblejas-L\u00f3pez","year":"2024","unstructured":"Noblejas-L\u00f3pez MDM, Garc\u00eda-Gil E, P\u00e9rez-Segura P, Pandiella A, Gy\u0151rffy B, Oca\u00f1a A. T-reg transcriptomic signatures identify response to check-point inhibitors. Sci Rep. 2024;14:10396.","journal-title":"Sci Rep"},{"key":"3786_CR71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2024;21:89\u2013105.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03786-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03786-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:02:38Z","timestamp":1779314558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03786-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":71,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,6,11]]}},"alternative-id":["3786"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03786-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in full accordance with relevant ethical principles and guidelines. The research design strictly adhered to the plan approved by the ethics committee. It complied with the ethical standards outlined in the Declaration of Helsinki and other applicable international regulations. Ethics approval was obtained from the Institutional Research Board of Harbin Medical University (Approval No. HMUIRB2023010). Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}